Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DZD7W6
|
|||
| Drug Name |
MK-2060
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Thrombosis [ICD-11: DB61-GB90] | Phase 2 | [1] | |
| Company |
Merck
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Coagulation factor XI (F11) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05027074) A Randomized Parallel-group, Placebo-controlled, Double-blind, Event-driven, Multi-center Phase 2 Clinical Outcome Trial of Prevention of Arteriovenous Graft Thrombosis and Safety of MK-2060 in Patients With End Stage Renal Disease Receiving Hemodialysis. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of MSD | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.